Novartis Wins Jury Verdict Over Zometa's Bone Death Risk

Law360, New York (May 15, 2013, 2:54 PM EDT) -- A New Jersey jury on Wednesday returned with a verdict for Novartis Pharmaceuticals Corp. in centralized litigation over its bone-strengthening drug Zometa, finding after a 13-day trial that the company did not fail to provide an adequate warning about dead jaw bone risks.

After fewer than six hours of deliberations starting Tuesday afternoon, the eight-member, all-male jury in Middlesex County Superior Court handed down its 7-1 decision in the case of Beverly Meng shortly after 11 a.m. Meng's lawsuit was the second to go on trial...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.